Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

KINAXO Extends Collaboration with Takeda

Published: Tuesday, April 05, 2011
Last Updated: Tuesday, April 05, 2011
Bookmark and Share
KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout ® to assist in research of drugs under development at Takeda.

KINAXO Biotechnologies GmbH has announced that it has entered a second collaboration with Takeda Pharmaceutical Company Limited Osaka, Japan. Under the agreement KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout ® to assist in research of drugs under development at Takeda. This will allow Takeda to take early educated decisions on drug efficacy and safety. Financial details of the agreement were not disclosed.

PhosphoScout® enables quantitative analysis of cellular phosphoproteomes on a global scale. Since signal transmission in eukaryotic cells is mainly regulated by reversible protein phosphorylation, comprehensive analysis of phosphoproteome modulation in response to drug treatment provide valuable insights into a drug’s mode of action.

Furthermore, PhosphoScout® can identify differentially regulated phosphorylation sites in vivo that may serve as pharmacodynamic or drug response biomarkers in clinical trials.

PhosphoScout® utilizes mass spectrometry methods enabling unbiased quantification of approx. 15,000 phosphorylation sites in a single experiment. Proprietary bioinformatic software tools are applied to visualize the drug’s effects on cellular signal transduction pathway and help identify phospho-protein biomarkers.

Dr. Andreas Jenne, KINAXO’s CEO said: “We are very pleased to continue our collaboration with Takeda, a world leading healthcare company, and look forward to supporting Takeda’s efforts in developing drugs. This collaboration once again demonstrates the power of our PhosphoScout® platform in drug discovery and development.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Kinaxo Enters in to an Agreement with AstraZeneca
Under the terms of the agreement, Kinaxo will apply its quantitative mass spec technology platform to support one of AstraZeneca’s oncology programs.
Wednesday, January 05, 2011
Kinaxo Extends its Collaboration with Roche
KINAXO will apply its phosphoproteomics technology PhosphoScout® to support targeted treatment approaches currently under development at Roche.
Wednesday, January 13, 2010
KINAXO Expands Technology Platform and Secures Additional Venture Capital
KINAXO is expanding its technology platform include mass spectrometry to serve the increasing demand of the pharmaceutical industry for chemical proteomics analyses.
Tuesday, May 08, 2007
Scientific News
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Detecting Fake Parmesan Cheeses
Scientists report on a way to catch adulteration of the regional artisanal products.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Process Analysis in Real Time
With a real-time mass spectrometer developed by Fraunhofer researchers, it has become possible for the first time to analyze up to 30 components simultaneously from the gas phase and a liquid, including in-situ analysis.
Triple-Negative Breast Cancer Target Is Found
Researchers at UC Berkeley discover a target that drives cancer metabolism in triple-negative breast cancer.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
A Mechanistic Tool for Studying Fungal Pathogens
This study presents an overview of lipid extraction, chromatographic separation and mass spectrometry employed in qualitative and quantitative sphingolipidomics in fungi.
Newborn Screening Test Developed For Rare, Deadly Neurological Disorder
Scientists have developed a new dried blood spot screening test for Niemann-Pick type C, with goal to speed diagnosis and treatment.
HIV Particles Used to Trap Intact Mammalian Protein Complexes
Belgian scientists from VIB and UGent developed Virotrap, a viral particle sorting approach for purifying protein complexes under native conditions.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!